Morgan Stanley says Anti-obesity drugs have trimmed market value by $258bn

<p>An interesting snippet from analysts at Morgan Stanely on a not-so-fat result:</p><ul><li>GLP-1 medications like Ozempic have seen a $340 billion uplift in market value for GLP-1 makers</li><li>And, offsetting that on the scales, “disrupted” stocks have lost around US$258 billion in market value</li><li>Analysts noted that consumer interest in the medications has weakened somewhat, but there has been a jump in company mentions of the trend on corporate conference calls …

“This disconnect between ‘main street’ vs ‘Wall Street’ excitement is typical of short-term hype cycle tops”</li></ul>

This article was written by Eamonn Sheridan at www.forexlive.com.